This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Study to Evaluate Tezepelumab on Airway Inflammati...
Clinical trial

Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE) (CASCADE)

Read time: 3 mins
Last updated:2nd Nov 2018
Identifier: NCT03688074

Brief Summary:
A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in adults with inadequately controlled asthma.

Detailed Description:
This is a multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in adults with inadequately controlled moderate-to-severe asthma, taking inhaled corticosteroids and at least one additional asthma controller. Approximately 110 subjects will be randomized globally. Subjects will receive tezepelumab, or placebo, administered via subcutaneous injection at the study site, over a 28-week treatment period. The study also includes a post-treatment follow-up period of 12 weeks.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 110 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Subjects will be randomized in a 1:1 ratio to either tezepelumab or matching placebo both administered subcutaneously.
Masking: Triple (Participant, Care Provider, Investigator)
Masking Description: Double-blind
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults With Inadequately Controlled Asthma on Inhaled Corticosteroids and at Least One Additional Asthma Controller (CASCADE)
Actual Study Start Date: November 2, 2018
Estimated Primary Completion Date: January 11, 2021
Estimated Study Completion Date: January 11, 2021

Arms:
- Experimental:
Tezepelumab
- Placebo Comparator: Placebo

Category Value
Date last updated at source 2019-09-19
Study type(s) Interventional
Expected enrolment 110
Study start date 2018-11-02
Estimated primary completion date 2021-01-11

View full details